The weight-loss medication industry is valued at $150 billion, with refills doubling in the past year. Eli Lilly’s Zepbound outperformed Novo Nordisk’s Wegovy in trials, and both companies are developing pill versions to replace injections. These medications could reduce the risk of cancer, diabetes, and heart disease, potentially saving healthcare costs long-term. However, efforts to get these drugs approved for Medicaid or Medicare face uncertainty.
https://linktr.ee/RobBlack.
#short #shorts #shortvideo #shortsvideo #trending #stocks #stockmarket #stock #market #finance #investing #investment #latest #fed #interestrates
